165 related articles for article (PubMed ID: 27709126)
1. Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.
Matthews QL; Farrow AL; Rachakonda G; Gu L; Nde P; Krendelchtchikov A; Pratap S; Sakhare SS; Sabbaj S; Lima MF; Villalta F
Pathog Immun; 2016; 1(2):214-233. PubMed ID: 27709126
[TBL] [Abstract][Full Text] [Related]
2. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.
Farrow AL; Rachakonda G; Gu L; Krendelchtchikova V; Nde PN; Pratap S; Lima MF; Villalta F; Matthews QL
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3089. PubMed ID: 25144771
[TBL] [Abstract][Full Text] [Related]
3. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.
Farrow AL; Peng BJ; Gu L; Krendelchtchikov A; Matthews QL
Viruses; 2016 Mar; 8(3):78. PubMed ID: 26978385
[TBL] [Abstract][Full Text] [Related]
4. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.
Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Galler R; Bonaldo MC
Virol J; 2011 Mar; 8():127. PubMed ID: 21418577
[TBL] [Abstract][Full Text] [Related]
5. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.
Gillis PA; Hernandez-Alvarado N; Gnanandarajah JS; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2014 Jun; 32(31):3963-70. PubMed ID: 24856783
[TBL] [Abstract][Full Text] [Related]
7. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.
Abe S; Okuda K; Ura T; Kondo A; Yoshida A; Yoshizaki S; Mizuguchi H; Klinman D; Shimada M
J Gene Med; 2009 Jul; 11(7):570-9. PubMed ID: 19391169
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
[TBL] [Abstract][Full Text] [Related]
10. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.
Medina GN; Montiel N; Diaz-San Segundo F; Sturza D; Ramirez-Medina E; Grubman MJ; de los Santos T
Clin Vaccine Immunol; 2015 Nov; 23(2):125-36. PubMed ID: 26607309
[TBL] [Abstract][Full Text] [Related]
12. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
13. Protective Efficacy of the Epitope-Conjugated Antigen N-Tc52/TSkb20 in Mitigating
Vázquez ME; Zabala BA; Mesías AC; Biscari L; Kaufman CD; Alloatti A; Siano F; Picariello G; Corbalán NS; Lenis BA; Toscano MA; Parodi CM; Brandán CMP; Acuña L
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932350
[TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
[TBL] [Abstract][Full Text] [Related]
15. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
[TBL] [Abstract][Full Text] [Related]
16. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response.
Moraes MP; Segundo FD; Dias CC; Pena L; Grubman MJ
Vaccine; 2011 Nov; 29(51):9431-40. PubMed ID: 22027486
[TBL] [Abstract][Full Text] [Related]
17. Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach.
Gu L; Icyuz M; Krendelchtchikova V; Krendelchtchikov A; Johnston AE; Matthews QL
Open Virol J; 2016; 10():10-20. PubMed ID: 27335626
[TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA
Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944
[TBL] [Abstract][Full Text] [Related]
19. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin Improves the Response of Effector and Memory CD8
Moraschi BF; Noronha IH; Ferreira CP; Cariste LM; Monteiro CB; Denapoli P; Vrechi T; Pereira GJS; Gazzinelli RT; Lannes-Vieira J; Rodrigues MM; Bortoluci KR; Vasconcelos JRC
Front Cell Infect Microbiol; 2021; 11():676183. PubMed ID: 34123875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
